Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis
Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis
复制标题
DOI：
10.1111/j.1872-034x.2007.00130.x
复制
发表时间：
2007-09-01
影响因子：
4.2
通讯作者：
Maeyama, Shiro
中科院分区：
文献类型：
--
作者：
Iijima, Hiroko;Moriyasu, Fuminori;Maeyama, Shiro
非酒精性脂肪性肝炎（NASH）是发达国家具有代表性的肝脏疾病之一。NASH的诊断依赖于肝活检的组织学结果。本文描述了超声造影与左旋造影在NASH诊断中的作用。静脉注射超声造影剂Levovist 2.5 g。分别于5、10、15、20、30、40、50分钟扫描肝脏，观察微泡积聚的变化。利用时间强度曲线（tic）测量和估计对比度图像上感兴趣区域（ROI）的信号强度。研究对象包括21例NASH患者、33例非酒精性脂肪性肝病（NAFLD）患者和10名健康志愿者（HV）。注射后5、20 min定量测量信号强度。与NAFLD和HV组相比，NASH的发生率有统计学意义上的显著降低。在组织学研究中，这些信号强度的变化与纤维化和脂肪变性的程度无关。当截断值为20 min信号强度的43.6时，受试者工作特征（ROC）曲线获得的灵敏度、特异度和总体准确度均为100%。Levovist对比研究是一种有用的筛选检查，可在脂肪肝患者中发现NASH。
Non-alcoholic steatohepatitis (NASH) is one of the representative liver diseases in developed countries. Diagnosis of NASH is dependent on histological findings from liver biopsy.The usefulness of contrast ultrasound with Levovist for diagnosis of NASH is described. 2.5 g of ultrasound contrast agent Levovist was injected intravenously. The liver was scanned at 5, 10, 15, 20, 30, 40 and 50 min and changes in microbubble accumulation were evaluated. The signal intensity from regions of interest (ROI) on the contrast images was measured and estimated using time intensity curves (TICs). Twenty-one patients with NASH, 33 with non-alcoholic fatty liver disease (NAFLD) and 10 healthy volunteers (HV) were studied. The signal intensity was measured quantitatively at 5 and 20 min after injection.There was a statistically significant decrease in NASH, when compared with NAFLD and HV groups. These changes in signal intensity were not correlated to the degree of fibrosis and steatosis in histological study. The sensitivity, specificity and overall accuracy obtained from the receiver operating characteristic (ROC) curve were 100% when the cut-off value was set at 43.6 of signal intensity at 20 min.The Levovist contrast study is a useful screening examination which picks up NASH among fatty liver patients.